Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 11/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 2/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.40 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1120796 | 0.93 | NR3C1 (0.43) | NR3C1MCL1BCL2PGRNR3C2 | |
| Hydrochloric Acid SCHEMBL1120842 | 0.92 | NR3C1 (0.43) | NR3C1MCL1BCL2PGRNR3C2 | |
| SCHEMBL1120828 | 0.84 | NR3C1 (0.41) | NR3C1MCL1PGRNR3C2AR | |
| SCHEMBL1120902 | 0.81 | NR3C1 (0.42) | KDM4EALDH1A1GAAMAPTNR3C1 | |
| SCHEMBL4484871 | 0.80 | KDM4E (0.44) | KDM4EALDH1A1NR3C1PGRNR3C2 | |
| SCHEMBL1120856 | 0.80 | NR3C1 (0.40) | ALDH1A1MAPTNR3C1MCL1PGR | |
| SCHEMBL1120786 | 0.80 | NR3C1 (0.45) | NR3C1MCL1PGRNR3C2AR | |
| SCHEMBL1120883 | 0.80 | NR3C1 (0.41) | SMN1; SMN2NR3C1PGRNR3C2AR | |
| Hydrochloric Acid SCHEMBL1120878 | 0.79 | NR3C1 (0.43) | NR3C1PGRNR3C2AR | |
| SCHEMBL1120830 | 0.79 | NR3C1 (0.39) | NR3C1PGRNR3C2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1935882-B1 | Bicyclic compounds | ASAHI KASEI PHARMA CORP (JP) | 2011-02-09 | — | — | EP | claimed |
| EP-1935882-A1 | Bicyclic compounds | Asahi Kasei Pharma Corporation (JP) | 2008-06-25 | — | — | EP | claimed |
| US-20080076815-A1 | Indole compounds as B3 androceptor agonist | ASHI KASEI PHARMA CORPORATION (JP) | 2008-03-27 | — | — | US | claimed |
| US-20050020602-A1 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-01-27 | — | — | US | claimed |
| EP-1447400-A1 | BICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2004-08-18 | — | — | EP | claimed |
| US-7598284-B2 | Indazole compounds as B3 adrenoceptor agonist | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-10-06 | — | — | US | disclosed |
| EP-1935882-A1 | Bicyclic compounds | Asahi Kasei Pharma Corporation (JP) | 2008-06-25 | — | — | EP | disclosed |
| US-20080076815-A1 | Indole compounds as B3 androceptor agonist | ASHI KASEI PHARMA CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20080015242-A1 | INDOLE COMPOUNDS AS BETA3 ANDROCEPTOR AGONIST | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-01-17 | — | — | US | disclosed |
| US-7271190-B2 | Indazole compounds as β3 adrenoceptor agonist | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-09-18 | — | — | US | disclosed |
| US-20050020602-A1 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1447400-A1 | BICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2004-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020602-A1 | Bicyclic compound | GOT1, H1-0, HSD11B1 | KDM4E 4236/4885ALDH1A1 741/4885GAA 4572/4885 |
| US-20080076815-A1 | Indole compounds as B3 androceptor agonist | OPRL1, NPBWR1, NPY4R | KDM4E 3516/4885ALDH1A1 3711/4885GAA 4868/4885 |
| US-20080015242-A1 | INDOLE COMPOUNDS AS BETA3 ANDROCEPTOR AGONIST | ADRB3, ADRB2, OPRD1 | KDM4E 4115/4885ALDH1A1 3156/4885GAA 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.